Your session is about to expire
← Back to Search
Romiplostim for Lymphoma
Study Summary
This trial will study whether a drug called romiplostim can help treat low platelet count caused by standard chemotherapy for lymphoma, as well as whether it can prevent the need for chemotherapy dose delays, reductions, or platelet transfusions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2010 Phase 3 trial • 313 Patients • NCT00116688Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can take care of myself but might not be able to do heavy physical work.I had severe low platelet counts from my last treatment.My organ functions are normal as of the start of my last treatment cycle.I am 18 or older and have been diagnosed with lymphoma.I have or had hepatitis with active infection indicators.My hemoglobin level is at least 7 g/dL, transfusions are okay.I haven't had serious heart issues like heart failure or a heart attack in the last 4 months.I am scheduled for at least one more round of chemotherapy.I agree to use effective birth control or abstain from sex during the study.I am on a chemotherapy treatment that lowers my platelet count and follows a 21-day cycle.I am 18 or older and have been diagnosed with lymphoma.I have not needed a platelet transfusion for low platelet count or bleeding.I have a blood cancer history, but it's not lymphoma, or I have lymphoma with specific conditions.My organs are functioning normally as of my last treatment cycle.I have had a stem cell transplant from a donor or CAR-T treatment.I have very low platelet counts or needed a transfusion for it.I can understand and am willing to sign the consent form myself or have a legal representative do it.I agree to use effective birth control or abstain from sex during the study.I have had blood clots but can't take blood thinners, or I've finished or am on a blood thinner treatment.I can take care of myself but might not be able to do heavy physical work.My white blood cell count is healthy enough for treatment.My hemoglobin level is at least 7 g/dL, transfusions are okay.I have a serious cancer that has spread and cannot be surgically removed, diagnosed within the last 5 years.I am HIV positive, on effective treatment, and have an undetectable viral load.I can understand and am willing to sign the consent form myself or have a legal representative do it.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I am on a chemotherapy treatment that lowers my platelet count and follows a 21-day cycle.I have not had major surgery in the last 26 days or minor surgery in the last 3 days.I have low platelet counts due to a condition called ITP.I am HIV positive, on effective treatment, and have an undetectable viral load.I had severe low platelet counts from my last treatment.My white blood cell count is healthy enough for treatment.I am scheduled for at least one more round of chemotherapy.I haven't had a heart attack or stroke in the last 4 months.
- Group 1: romiplostim
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals can join this clinical research project?
"That is correct. The online information states that the research team is actively looking for 20 individuals to participate in this study at 8 different locations."
Does Romiplostim have a history of clinical trials?
"Bergen's Memorial Sloan Kettering was the first to study romiplostim back in 2014. As of right now, 41 studies have been completed while 9 are ongoing. The majority of these active trials are based in Commack, New york."
Does Romiplostim have any dangerous side-effects?
"Romiplostim's safety is based on Phase 2 trial data, which means that while there is evidence suggesting it is safe, there is no supporting data for its efficacy."
Are there any open slots for this research project?
"Yes, the information on clinicaltrials.gov indicates that this study is still looking for patients to enroll. The original posting was on December 14th 2020 and it has been updated as recently as June 20th of 2022. They are recruiting for a total of 20 participants across 8 locations."
Is this research being conducted for the first time?
"Romiplostim has been under clinical observation since 2014 when Amgen first sponsored a study. After the initial 60 person trial, Romiplostim received Phase 2 drug approval in 2014. Now, 9 years later, there are active studies involving Romiplostim happening in 62 cities across 23 countries."
Where are patients able to participate in this research?
"There are 8 active clinical trial sites for this study, which are situated in Commack, Miami, Uniondale and other cities. If you enroll in the study, it is important to try and select a location that is close to minimize travel requirements."
Share this study with friends
Copy Link
Messenger